The average tumor size for these patients before treatment was 5.75±0.43 cm, and the pathological size of the surgical specimens was 2.89±0.41 cm; a total of five of these patients achieved pathologic complete response in the breast and axilla: three HER-2-positive patients and two luminal B patients. This evidence concerns the gene ERBB2 and neoplasm.